MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease

Journal of Digestive Diseases

Volumn 17, Issue 11, 2016, Pages 708-715

  Liu, Xiao Lin ^a   Cao, Hai Xia ^a   Fan, Jian Gao ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

biomarkers; microRNAs; nonalcoholic fatty liver disease; pathogenesis

Indexed keywords

MICRORNA; MICRORNA 125A 5P; MICRORNA 125B; MICRORNA 1290; MICRORNA 146A; MICRORNA 150; MICRORNA 15B; MICRORNA 16; MICRORNA 17; MICRORNA 181D; MICRORNA 182; MICRORNA 183; MICRORNA 192; MICRORNA 197; MICRORNA 21; MICRORNA 219A; MICRORNA 22; MICRORNA 221; MICRORNA 224; MICRORNA 26A; MICRORNA 27B; MICRORNA 31; MICRORNA 34A; MICRORNA 378I; MICRORNA 590; MICRORNA 615; MICRORNA 7; MICRORNA 92B; MICRORNA 99A; UNCLASSIFIED DRUG; UNINDEXED DRUG; GENETIC MARKER;

APOPTOSIS; DIAGNOSTIC VALUE; ENDOPLASMIC RETICULUM STRESS; HEPATITIS; HUMAN; LIPID METABOLISM; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; LIVER; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; EPIGENESIS, GENETIC; GENETIC MARKERS; HUMANS; LIVER; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 85009274723     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12408     Document Type: Review

References (79)

1. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–23.
2. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519–23.
3. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721–8.
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330–44.
5. Sumida Y, Eguchi Y, Ono M. Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. World J Hepatol 2010; 2: 374–83.
6. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–112.
7. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4–12.
8. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774–88.
9. Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci 2015; 16: 5161–79.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–97.
11. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239–50.
12. Williams MD, Mitchell GM. MicroRNAs in insulin resistance and obesity. Exp Diabetes Res 2012; 2012: 484696.
13. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012; 9: 850–9.
14. Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol 2014; 34: 726–32.
15. Yamada H, Ohashi K, Suzuki K et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta 2015; 446: 267–71.
16. Yamada H, Suzuki K, Ichino N et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013; 424: 99–103.
17. Tryndyak VP, Latendresse JR, Montgomery B et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol 2012; 262: 52–9.
18. Pirola CJ, Fernández Gianotti T, Castaño GO et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800–12.
19. Cheung O, Puri P, Eicken C et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810–20.
20. Miyaaki H, Ichikawa T, Kamo Y et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014; 34: e302–7.
21. Braza-Boïls A, Marí-Alexandre J, Molina P et al. Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease. Liver Int 2016; 36: 1221–9.
22. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937.
23. Luna JM, Michailidis E, Rice CM. Mopping up miRNA: an integrated HBV transcript disrupts liver homeostasis by sequestering miR-122. J Hepatol 2016; 64: 257–9.
24. Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016; 6: 21340.
25. McGill MR, Jaeschke H. MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury. J Clin Med 2015; 4: 1063–78.
26. Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO. Association of circulating serum miR-34a and miR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS One 2016; 11: e0153497.
27. Li S, Chen X, Zhang H et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009; 50: 1756–65.
28. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNA panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014; 9: e105192.
29. Becker PP, Rau M, Schmitt J et al. Performance of serum microRNA -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One 2015; 10: e0142661.
30. Roy S, Benz F, Alder J et al. Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. Clin Sci (Lond) 2016; 130: 1197–207.
31. Sharma H, Estep M, Birerdinc A et al. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2013; 28: 1410–5.
32. Celikbilek M, Baskol M, Taheri S et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6: 613–20.
33. Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR, Fu JF. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem 2014; 34: 1983–97.
34. Zhang Y, Cheng X, Lu Z et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res Clin Pract 2013; 99: 327–34.
35. Xu Q, Li Y, Shang YF, Wang HL, Yao MX. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21: 511–6.
36. Akuta N, Kawamura Y, Suzuki F et al. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 2016; 10: 647–56.
37. Bihrer V, Friedrich-Rust M, Kronenberger B et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106: 1663–9.
38. Lu M, Zhang Q, Deng M et al. An analysis of human microRNA and disease associations. PLoS One 2008; 3: e3420.
39. Guo CJ, Pan Q, Li DG, Sun H, Liu BW. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol 2009; 50: 766–78.
40. Pan Q, Guo C, Sun C, Fan J, Fang C. Integrative analysis of the transcriptome and targetome identifies the regulatory network of miR-16: an inhibitory role against the activation of hepatic stellate cells. Biomed Mater Eng 2014; 24: 3863–71.
41. Estep M, Armistead D, Hossain N et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 32: 487–97.
42. Leti F, Malenica I, Doshi M et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res 2015; 166: 304–14.
43. Halász T, Horváth G, Pár G et al. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol 2015; 21: 7814–23.
44. Tessitore A, Cicciarelli G, Del Vecchio F et al. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer 2016; 16: 3.
45. Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol 2016; 51: 1022–30.
46. Castoldi M, Vujic Spasic M, Altamura S et al. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 2011; 121: 1386–96.
47. Esau C, Davis S, Murray SF et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87–98.
48. Castro RE, Ferreira DM, Afonso MB et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013; 58: 119–25.
49. Ding J, Li M, Wan X et al. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep 2015; 5: 13729.
50. Min HK, Kapoor A, Fuchs M et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665–74.
51. Xu Y, Zalzala M, Xu J, Li Y, Yin L, Zhang Y. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun 2015; 6: 7466.
52. Shan W, Gao L, Zeng W et al. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease. Cell Death Dis 2015; 6: e1833.
53. Ferreira DM, Afonso MB, Rodrigues PM et al. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol 2014; 34: 1100–20.
54. Sun C, Huang F, Liu X et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med 2015; 35: 847–53.
55. Ahn J, Lee H, Jung CH, Ha T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res 2012; 56: 1665–74.
56. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 2016; 65: 1850–60.
57. Najafi-Shoushtari SH, Kristo F, Li Y et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566–9.
58. Li T, Francl JM, Boehme S, Chiang JY. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7α-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatology 2013; 58: 1111–21.
59. Dávalos A, Goedeke L, Smibert P et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011; 108: 9232–7.
60. Horie T, Nishino T, Baba O et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2013; 4: 2883.
61. Ahn J, Lee H, Chung CH, Ha T. High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. Biochem Biophys Res Commun 2011; 414: 664–9.
62. Zhang B, Wang R, Du J et al. Upregulated microRNA-199a-5p inhibits nuclear receptor corepressor 1 translation in mice with non-alcoholic steatohepatitis. Mol Med Rep 2014; 10: 3080–6.
63. Nakanishi N, Nakagawa Y, Tokushige N et al. The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice. Biochem Biophys Res Commun 2009; 385: 492–6.
64. Zheng L, Lv GC, Sheng J, Yang YD. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-α expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol 2010; 25: 156–63.
65. Zhang ZC, Liu Y, Xiao LL et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol 2015; 63: 1466–75.
66. Ng R, Wu H, Xiao H et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 2014; 60: 554–64.
67. Xiao J, Lv D, Zhao Y et al. miR-149 controls non-alcoholic fatty liver by targeting FGF-21. J Cell Mol Med 2016; 20: 1603–8.
68. Cazanave SC, Mott JL, Elmi NA et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res 2011; 52: 1517–25.
69. Meng X, Guo J, Fang W et al. Liver microRNA-291b-3p promotes hepatic lipogenesis through negative regulation of adenosine 5'-monophosphate (AMP)-activated protein kinase α1. J Biol Chem 2016; 291: 10625–34.
70. Lin X, Jia J, Du T et al. Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism. PLoS One 2015; 10: e0118417.
71. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836–46.
72. Tian H, Liu C, Zou X, Wu W, Zhang C, Yuan D. MiRNA-194 regulates palmitic acid-induced toll-like receptor 4 inflammatory responses in THP-1 cells. Nutrients 2015; 7: 3483–96.
73. Hur W, Lee JH, Kim SW et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int J Biochem Cell Biol 2015; 64: 265–76.
74. Jiang W, Liu J, Dai Y, Zhou N, Ji C, Li X. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. J Gastroenterol Hepatol 2015; 30: 933–43.
75. Li D, Wang X, Lan X et al. Down-regulation of miR-144 elicits proinflammatory cytokine production by targeting toll-like receptor 2 in nonalcoholic steatohepatitis of high-fat-diet-induced metabolic syndrome E3 rats. Mol Cell Endocrinol 2015; 402: 1–12.
76. Miyamoto Y, Mauer AS, Kumar S, Mott JL, Malhi H. Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein. PLoS One 2014; 9: e109637.
77. Du J, Niu X, Wang Y et al. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a. Sci Rep 2015; 5: 16163.
78. Albulescu R, Neagu M, Albulescu L, Tanase C. Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Rev Mol Diagn 2011; 11: 101–20.
79. Shah N, Nelson JE, Kowdley KV. MicroRNAs in liver disease: bench to bedside. J Clin Exp Hepatol 2013; 3: 231–42.